Edap TMS SA, a leader in robotic energy-based therapies, reported strong results for the second quarter of 2025, with notable growth in its High-Intensity Focused Ultrasound (HIFU) segment. The company saw a 140% year-over-year increase in Focal One® net placements and a 76.8% rise in HIFU revenue. The company has raised its 2025 HIFU year-over-year revenue growth guidance to a range of 26% to 34%, up from the previous range of 16% to 25%. Total worldwide revenue for the second quarter of 2025 increased by 1.6% to EUR 16.0 million (USD 18.4 million) from EUR 15.8 million (USD 17.0 million) in the same period of 2024. The company reported a gross profit of EUR 12.5 million (USD 13.8 million) for the first half of 2025, up from EUR 12.3 million (USD 13.3 million) in the first half of 2024, with a gross profit margin on net sales of 42.3%, compared to 40.1% in the previous year. However, Edap TMS SA recorded an operating loss of EUR 11.8 million (USD 13.0 million) for the first six months of 2025, compared to an operating loss of EUR 11.0 million (USD 11.8 million) in the same period of 2024. The company executed a letter of intent for a 36 million Euro credit facility with the European Investment Bank (EIB) to support further HIFU growth and strategic expansion. Additionally, Edap TMS announced that as of January 1, 2026, it will become a U.S. domestic filer and comply with U.S. SEC reporting rules and Nasdaq listing requirements. The company also launched the new Focal One i Robotic HIFU System and presented positive final 3-year outcomes of its FARP Randomized Controlled Trial at the 120th AUA Annual Meeting.